Press release
Anaplastic Thyroid Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Anaplastic Thyroid Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Anaplastic Thyroid Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report
* In August 2025, University of Arizona announced a Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites.
* DelveInsight's Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment.
* The leading Anaplastic Thyroid Cancer Companies such as Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
* Promising Anaplastic Thyroid Cancer Pipeline Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar,BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others.
Stay ahead with the most recent pipeline outlook for Anaplastic Thyroid Cancer. Get insights into clinical trials, emerging therapies, and leading companies with Anaplastic Thyroid Cancer @ Anaplastic Thyroid Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Anaplastic Thyroid Cancer Emerging Drugs Profile
* Sapanisertib: Takeda
Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types. Sapanisertib has demonstrated promising single-agent activity in patients with relapsed/refractory NRF2-mutated squamous non-small cell lung cancer (NSCLC) and exhibits differential anti-tumor activity compared to rapalog inhibitors of TORC1 in NRF2-mutant squamous NSCLC in vivo models.
* HLX208: Shanghai Henlius Biotech
BRAF V600E small-molecule inhibitor can be potentially used in the treatment of various solid tumors. HLX208 may be combined with the Company's proprietary EGFR or PD-1 targeted antibodies to enhance a high-quality, innovative and differentiated product portfolio for the treatment of various cancer types.
The Anaplastic Thyroid Cancer Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Anaplastic Thyroid Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment.
* Anaplastic Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Anaplastic Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anaplastic Thyroid Cancer market
Explore groundbreaking therapies and clinical trials in the Anaplastic Thyroid Cancer Pipeline. Access DelveInsight's detailed report now! @ New Anaplastic Thyroid Cancer Drugs [https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Anaplastic Thyroid Cancer Companies
Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
Anaplastic Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Anaplastic Thyroid Cancer Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
Unveil the future of Anaplastic Thyroid Cancer Treatment. Learn about new drugs, Anaplastic Thyroid Cancer Pipeline developments, and key companies with DelveInsight's expert analysis @ Anaplastic Thyroid Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Anaplastic Thyroid Cancer Pipeline Report
* Coverage- Global
* Anaplastic Thyroid Cancer Companies- Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
* Anaplastic Thyroid Cancer Pipeline Therapies- Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar, BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others.
* Anaplastic Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Anaplastic Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Anaplastic Thyroid Cancer Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Anaplastic Thyroid Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Anaplastic Thyroid Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Anaplastic Thyroid Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Sapanisertib: Takeda
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AIC100: AffyImmune Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Anaplastic Thyroid Cancer Key Companies
* Anaplastic Thyroid Cancer Key Products
* Anaplastic Thyroid Cancer- Unmet Needs
* Anaplastic Thyroid Cancer- Market Drivers and Barriers
* Anaplastic Thyroid Cancer- Future Perspectives and Conclusion
* Anaplastic Thyroid Cancer Analyst Views
* Anaplastic Thyroid Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=anaplastic-thyroid-cancer-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anaplastic Thyroid Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4150790 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Anaplastic
Anaplastic Astrocytoma Market Outlook, Epidemiology, Landscape and Growth Trajec …
Anaplastic astrocytoma (AA) is a rare, malignant brain tumor classified as World Health Organization (WHO) Grade III glioma, characterized by its aggressive nature and poor prognosis. While not as common as glioblastoma, anaplastic astrocytoma represents a significant challenge due to its high recurrence rates, limited treatment options, and resistance to conventional therapies.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70897
Over the past decade, the treatment landscape has slowly evolved…
Anaplastic Large Cell Lymphoma Drugs Market: An In-Depth Analysis
The global Anaplastic Large Cell Lymphoma Drugs market was valued approximately USD 10.5 billion in 2022 and is projected to reach around USD 17.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5% during the forecast period.
Anaplastic Large Cell Lymphoma Drugs Market Overview
Anaplastic Large Cell Lymphoma is a rare type of non-Hodgkin lymphoma characterized by the proliferation of large lymphoid cells. The market for ALCL…
Anaplastic Astrocytoma Market Development, Trends, Segmentations Analysis
Anaplastic astrocytoma is a very rare type of malignant brain tumor affecting human at all ages. As this tumor develops from astrocytes, the star-shaped brain cells it is termed as astrocytoma. The astrocytes along with other cells protect nerve cells in the brain and spinal cord by surrounding them. All these protective cells are collectively termed as glial cells. World Health Organization (WHO) graded these tumors on a scale from…
Anaplastic Astrocytoma - Pipeline Review, H2 2017 - Pharmaceutical Report
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among…
Anaplastic Oligoastrocytoma Market Snapshot by 2024 – Persistence Market Resea …
Oligoastrocytomas is a part of a group of brain tumor called “gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is divided into two parts, low grade and anaplastic. According to the WHO grading system, anaplastic oligoastrocytomas are usually identify as grade 1 and grade 2 but sometimes they appear…
Latest Report Details Of Global Anaplastic Thyroid Cancer Market
Marketresearchreports.biz has added a new research report on the "Anaplastic Thyroid Cancer-Pipeline Insights, 2017" to its collection.
DelveInsights, Anaplastic Thyroid Cancer- Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Thyroid Cancer. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical…
